Evidence map›Paper›PMID 36157459›Full record

ArticleFrontiers in endocrinology2022

Semiquantitative assessment of

Dafu Yu, Lin Zou, Yao Jin, Mingxiang Wei, Xiaoqun Wu, Lingjing Zuo, Mingkang Wu, Yong Jiang

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dafu YuDepartment of Nuclear Medicine, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Lin ZouDepartment of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yao JinDepartment of Nuclear Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Mingxiang WeiDepartment of Nuclear Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Xiaoqun WuDepartment of Respiratory Disease, The First People's Hospital of Yunnan Province, Kunming, China.
Lingjing ZuoDepartment of Nuclear Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Mingkang WuDepartment of Nuclear Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Yong JiangDepartment of Nuclear Medicine, The First People's Hospital of Yunnan Province, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the valuably influential factors and improve the diagnostic accuracy and efficiency of Methods: The correlation analysis was performed between clinical indices related to CRF and Results: MIBI uptake was significantly positively related to patient age, CRF course, hemodialysis vintage, serum parathyroid hormone (PTH), and alkaline phosphatase (AKP) but was significantly negatively related to serum uric acid (UA). MIBI washout was significantly positively related to patient age but was significantly negatively related to serum phosphorus (P) and calcium (Ca) × P. Oral administration of calcitriol and calcium could significantly reduce the MIBI uptake. MIBI uptake tendency might alter. Such seven indices, namely the MIBI uptake, CRF course, hemodialysis vintage, serum AKP, calcium, cysteine proteinase inhibitor C, and PTH, were comparable between the slight and medium groups but were significantly different between the slight and high groups or between the medium and high groups. The above seven indices plus blood urea nitrogen/creatinine were all significantly different between the insignificant and significant groups. All above significances were with Conclusions: Patient age, CRF course, hemodialysis vintage, serum PTH, AKP, UA, phosphorus, Ca × P, oral administration of calcitriol and calcium, and parathyroids themselves can significantly influence MIBI uptake in parathyroids of SHPT patients with CRF. The two-level grouping method of MIBI intensity should be adopted to qualitatively diagnose the MIBI uptake.

Indexed as

Hyperparathyroidism, SecondaryKidney Failure, ChronicAlkaline PhosphataseCalcitriolCalciumCreatinineCysteine Proteinase InhibitorsHumansParathyroid HormonePhosphorusTechnetium Tc 99m SestamibiUric AcidAlkaline PhosphataseCalcitriolCalciumCreatinineCysteine Proteinase InhibitorsParathyroid HormonePhosphorusTechnetium Tc 99m SestamibiUric Acid99mTc-methoxyisobutylisonitrile (MIBI)chronic renal failureparathyroidssecondary hyperparathyroidismsemiquantitative assessment

Identifiers

PMID36157459
PMCPMC9492857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.